Showing results (91-100 of 107) with videos related to

Sort By:
Pageof 11
Gene Therapy|March 15, 2002
Therapy of lung metastases through combined vaccination with carcinoma cells engineered to release IL-13 and IFN-gammaC De Giovanni, G Nicoletti, L Landuzzi, et al.
The American Journal of Pathology|December 7, 2000
The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kitL Landuzzi, C De Giovanni, G Nicoletti, et al.
Oncogene|February 16, 1999
The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cellsK Scotlandi, M C Manara, M Serra, et al.
International Journal of Cancer|May 29, 1997
Expression of interleukin 15 (IL-15) in human rhabdomyosarcoma, osteosarcoma and Ewing's sarcomaP L Lollini, G Palmieri, C De Giovanni, et al.
British Journal of Cancer|December 23, 1998
Wild-type p53-mediated down-modulation of interleukin 15 and interleukin 15 receptors in human rhabdomyosarcoma cellsC De Giovanni, P Nanni, A Sacchi, et al.
Clinical and Experimental Medicine|February 20, 2009
Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors modelM A Pantaleo, L Landuzzi, G Nicoletti, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 8, 2000
Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytesM Giovarelli, P Cappello, G Forni, et al.
Oncogene|February 1, 2011
Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signalingC Garofalo, M C Manara, G Nicoletti, et al.
The Journal of Experimental Medicine|November 7, 2001
Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic miceP Nanni, G Nicoletti, C De Giovanni, et al.
Oncogene|September 20, 2016
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancerL Castagnoli, G C Ghedini, A Koschorke, et al.
Pageof 11